agarose streptavidin  (Vector Laboratories)


Bioz Verified Symbol Vector Laboratories is a verified supplier
Bioz Manufacturer Symbol Vector Laboratories manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Vector Laboratories agarose streptavidin
    C6S-p binds to CD44 and accelerates CD44 degradation. ( A ) Co-localization between CD44 and C6S-binding peptides. Peptides staining with biotin (red) and CD44 antibody (green). Scale bar 8 μm. Amplified images are shown. ( B ) <t>Streptavidin</t> beads pulldown assay isolated the CD44-C6S-p complex. A172 cell lysate was used for the biotinylated peptide pulldown assay. Protein levels of CD44 were analyzed by Western blotting. ( C ) Western blotting of CD44 degradation. A172 cells were treated with peptides and 20 μM cycloheximide (CHX) for 30, 60 and 120 min. Actin was used as the loading control. The relative protein levels are shown on the right. ** p
    Agarose Streptavidin, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/agarose streptavidin/product/Vector Laboratories
    Average 94 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    agarose streptavidin - by Bioz Stars, 2022-11
    94/100 stars

    Images

    1) Product Images from "Targeting Chondroitin Sulfate Reduces Invasiveness of Glioma Cells by Suppressing CD44 and Integrin β1 Expression"

    Article Title: Targeting Chondroitin Sulfate Reduces Invasiveness of Glioma Cells by Suppressing CD44 and Integrin β1 Expression

    Journal: Cells

    doi: 10.3390/cells10123594

    C6S-p binds to CD44 and accelerates CD44 degradation. ( A ) Co-localization between CD44 and C6S-binding peptides. Peptides staining with biotin (red) and CD44 antibody (green). Scale bar 8 μm. Amplified images are shown. ( B ) Streptavidin beads pulldown assay isolated the CD44-C6S-p complex. A172 cell lysate was used for the biotinylated peptide pulldown assay. Protein levels of CD44 were analyzed by Western blotting. ( C ) Western blotting of CD44 degradation. A172 cells were treated with peptides and 20 μM cycloheximide (CHX) for 30, 60 and 120 min. Actin was used as the loading control. The relative protein levels are shown on the right. ** p
    Figure Legend Snippet: C6S-p binds to CD44 and accelerates CD44 degradation. ( A ) Co-localization between CD44 and C6S-binding peptides. Peptides staining with biotin (red) and CD44 antibody (green). Scale bar 8 μm. Amplified images are shown. ( B ) Streptavidin beads pulldown assay isolated the CD44-C6S-p complex. A172 cell lysate was used for the biotinylated peptide pulldown assay. Protein levels of CD44 were analyzed by Western blotting. ( C ) Western blotting of CD44 degradation. A172 cells were treated with peptides and 20 μM cycloheximide (CHX) for 30, 60 and 120 min. Actin was used as the loading control. The relative protein levels are shown on the right. ** p

    Techniques Used: Binding Assay, Staining, Amplification, Isolation, Western Blot

    Effects of CS-binding peptide (C6S-p) on glioma cells. ( A ) Immunocytochemistry of biotin staining with streptavidin-Alexa 594 (red) and nuclear with DAPI (blue). A172 cells were treated with PBS or C6S-p for 20 min or C6S-p for 120 min. Scale bar, 12.5 μm. Amplified images are shown at lower panel. ( B ) A CCK8 assay was used for detecting the effect of C6S-p on the viability of A172 cells. Treatment with different doses (10, 50, and 100 μg) of C6S-p or the control scrambled peptide for 24 h (left); and the time course treatment with 100 μg of C6S-p or control scrambled peptide for 24, 48, and 72 h (right). Cell viability is represented as percentage relative to the control group. ( C ) Scratch assays in GL261 and A172 glioma cells treated with C6S-p or the scrambled peptide; the average area of wound closure is shown as a percentage relative to control. ( D ) Matrigel invasion assays in GL261 and A172 glioma treated with C6S-p or the scrambled peptide; migrated cells are shown as the number of invaded cells per field. ( E ) Examining the ex vivo migration of A172 cells transfected with control siRNA (Ctr si) or CHSY1-siRNA (CHSY1 si, upper) and A172 cells treated with scrambled peptide or C6S-p (lower) on mouse brain tissue slice. The white circles indicate the original location of the cell seeding at day 0, and the red line indicates the cell moving edge after 72 h. Representative images are shown. Scale bars, 150 μm. The mean ± SD of area changes from four independent experiments were shown at bottom. Statistical significance, ** p
    Figure Legend Snippet: Effects of CS-binding peptide (C6S-p) on glioma cells. ( A ) Immunocytochemistry of biotin staining with streptavidin-Alexa 594 (red) and nuclear with DAPI (blue). A172 cells were treated with PBS or C6S-p for 20 min or C6S-p for 120 min. Scale bar, 12.5 μm. Amplified images are shown at lower panel. ( B ) A CCK8 assay was used for detecting the effect of C6S-p on the viability of A172 cells. Treatment with different doses (10, 50, and 100 μg) of C6S-p or the control scrambled peptide for 24 h (left); and the time course treatment with 100 μg of C6S-p or control scrambled peptide for 24, 48, and 72 h (right). Cell viability is represented as percentage relative to the control group. ( C ) Scratch assays in GL261 and A172 glioma cells treated with C6S-p or the scrambled peptide; the average area of wound closure is shown as a percentage relative to control. ( D ) Matrigel invasion assays in GL261 and A172 glioma treated with C6S-p or the scrambled peptide; migrated cells are shown as the number of invaded cells per field. ( E ) Examining the ex vivo migration of A172 cells transfected with control siRNA (Ctr si) or CHSY1-siRNA (CHSY1 si, upper) and A172 cells treated with scrambled peptide or C6S-p (lower) on mouse brain tissue slice. The white circles indicate the original location of the cell seeding at day 0, and the red line indicates the cell moving edge after 72 h. Representative images are shown. Scale bars, 150 μm. The mean ± SD of area changes from four independent experiments were shown at bottom. Statistical significance, ** p

    Techniques Used: Binding Assay, Immunocytochemistry, Staining, Amplification, CCK-8 Assay, Ex Vivo, Migration, Transfection

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Vector Laboratories agarose streptavidin
    C6S-p binds to CD44 and accelerates CD44 degradation. ( A ) Co-localization between CD44 and C6S-binding peptides. Peptides staining with biotin (red) and CD44 antibody (green). Scale bar 8 μm. Amplified images are shown. ( B ) <t>Streptavidin</t> beads pulldown assay isolated the CD44-C6S-p complex. A172 cell lysate was used for the biotinylated peptide pulldown assay. Protein levels of CD44 were analyzed by Western blotting. ( C ) Western blotting of CD44 degradation. A172 cells were treated with peptides and 20 μM cycloheximide (CHX) for 30, 60 and 120 min. Actin was used as the loading control. The relative protein levels are shown on the right. ** p
    Agarose Streptavidin, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/agarose streptavidin/product/Vector Laboratories
    Average 94 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    agarose streptavidin - by Bioz Stars, 2022-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    C6S-p binds to CD44 and accelerates CD44 degradation. ( A ) Co-localization between CD44 and C6S-binding peptides. Peptides staining with biotin (red) and CD44 antibody (green). Scale bar 8 μm. Amplified images are shown. ( B ) Streptavidin beads pulldown assay isolated the CD44-C6S-p complex. A172 cell lysate was used for the biotinylated peptide pulldown assay. Protein levels of CD44 were analyzed by Western blotting. ( C ) Western blotting of CD44 degradation. A172 cells were treated with peptides and 20 μM cycloheximide (CHX) for 30, 60 and 120 min. Actin was used as the loading control. The relative protein levels are shown on the right. ** p

    Journal: Cells

    Article Title: Targeting Chondroitin Sulfate Reduces Invasiveness of Glioma Cells by Suppressing CD44 and Integrin β1 Expression

    doi: 10.3390/cells10123594

    Figure Lengend Snippet: C6S-p binds to CD44 and accelerates CD44 degradation. ( A ) Co-localization between CD44 and C6S-binding peptides. Peptides staining with biotin (red) and CD44 antibody (green). Scale bar 8 μm. Amplified images are shown. ( B ) Streptavidin beads pulldown assay isolated the CD44-C6S-p complex. A172 cell lysate was used for the biotinylated peptide pulldown assay. Protein levels of CD44 were analyzed by Western blotting. ( C ) Western blotting of CD44 degradation. A172 cells were treated with peptides and 20 μM cycloheximide (CHX) for 30, 60 and 120 min. Actin was used as the loading control. The relative protein levels are shown on the right. ** p

    Article Snippet: For the C6S-p pulldown assay, a total 0.8 mg of cell lysate was mixed with C6S-p gently and incubated at 4 °C for 16 h. Streptavidin beads (Vector Laboratories, SA-5010, Burlingame, CA, USA) were added to the lysate and incubated for 3 h. The bead pulldown samples were analyzed by Western blotting.

    Techniques: Binding Assay, Staining, Amplification, Isolation, Western Blot

    Effects of CS-binding peptide (C6S-p) on glioma cells. ( A ) Immunocytochemistry of biotin staining with streptavidin-Alexa 594 (red) and nuclear with DAPI (blue). A172 cells were treated with PBS or C6S-p for 20 min or C6S-p for 120 min. Scale bar, 12.5 μm. Amplified images are shown at lower panel. ( B ) A CCK8 assay was used for detecting the effect of C6S-p on the viability of A172 cells. Treatment with different doses (10, 50, and 100 μg) of C6S-p or the control scrambled peptide for 24 h (left); and the time course treatment with 100 μg of C6S-p or control scrambled peptide for 24, 48, and 72 h (right). Cell viability is represented as percentage relative to the control group. ( C ) Scratch assays in GL261 and A172 glioma cells treated with C6S-p or the scrambled peptide; the average area of wound closure is shown as a percentage relative to control. ( D ) Matrigel invasion assays in GL261 and A172 glioma treated with C6S-p or the scrambled peptide; migrated cells are shown as the number of invaded cells per field. ( E ) Examining the ex vivo migration of A172 cells transfected with control siRNA (Ctr si) or CHSY1-siRNA (CHSY1 si, upper) and A172 cells treated with scrambled peptide or C6S-p (lower) on mouse brain tissue slice. The white circles indicate the original location of the cell seeding at day 0, and the red line indicates the cell moving edge after 72 h. Representative images are shown. Scale bars, 150 μm. The mean ± SD of area changes from four independent experiments were shown at bottom. Statistical significance, ** p

    Journal: Cells

    Article Title: Targeting Chondroitin Sulfate Reduces Invasiveness of Glioma Cells by Suppressing CD44 and Integrin β1 Expression

    doi: 10.3390/cells10123594

    Figure Lengend Snippet: Effects of CS-binding peptide (C6S-p) on glioma cells. ( A ) Immunocytochemistry of biotin staining with streptavidin-Alexa 594 (red) and nuclear with DAPI (blue). A172 cells were treated with PBS or C6S-p for 20 min or C6S-p for 120 min. Scale bar, 12.5 μm. Amplified images are shown at lower panel. ( B ) A CCK8 assay was used for detecting the effect of C6S-p on the viability of A172 cells. Treatment with different doses (10, 50, and 100 μg) of C6S-p or the control scrambled peptide for 24 h (left); and the time course treatment with 100 μg of C6S-p or control scrambled peptide for 24, 48, and 72 h (right). Cell viability is represented as percentage relative to the control group. ( C ) Scratch assays in GL261 and A172 glioma cells treated with C6S-p or the scrambled peptide; the average area of wound closure is shown as a percentage relative to control. ( D ) Matrigel invasion assays in GL261 and A172 glioma treated with C6S-p or the scrambled peptide; migrated cells are shown as the number of invaded cells per field. ( E ) Examining the ex vivo migration of A172 cells transfected with control siRNA (Ctr si) or CHSY1-siRNA (CHSY1 si, upper) and A172 cells treated with scrambled peptide or C6S-p (lower) on mouse brain tissue slice. The white circles indicate the original location of the cell seeding at day 0, and the red line indicates the cell moving edge after 72 h. Representative images are shown. Scale bars, 150 μm. The mean ± SD of area changes from four independent experiments were shown at bottom. Statistical significance, ** p

    Article Snippet: For the C6S-p pulldown assay, a total 0.8 mg of cell lysate was mixed with C6S-p gently and incubated at 4 °C for 16 h. Streptavidin beads (Vector Laboratories, SA-5010, Burlingame, CA, USA) were added to the lysate and incubated for 3 h. The bead pulldown samples were analyzed by Western blotting.

    Techniques: Binding Assay, Immunocytochemistry, Staining, Amplification, CCK-8 Assay, Ex Vivo, Migration, Transfection